Taiho Pharma moves US court against Natco for patent infringement

Topics Natco | Natco Pharma | Patent

Representative Image

Taiho Pharmaceutical, a Japanese pharmaceuticals company and its group company have moved a US court against Natco Pharma, alleging that the Indian drug maker was attempting to come out with a generic version of its cancer medicine 'Lonsurf,' before expiration of its patent.

In a petition filed in the United States District Court for the District Court of Delawareon December 30, Taiho alleged that the Indian drug maker's proposed generic Lonsurf (trifluridine and tipiracil) will infringe the patent and sought the court to pass an injunction order against manufacturing, importing and selling that drug in the US.

Taiho Oncology, Inc. sells and distributes Lonsurf in the United States, while Taiho Pharmaceuticalis the owner of all the right, title, and interest of the patent.

The Japanese company sought the court to pass an injunction order enjoining Natco from attempting to manufacture or sell Lonsurf in the US.

Earlier in November, 2019, through a letter to Taiho,the Indian drug makernotified that it submitted ANDA (abbreviated new drug application) to the US FDA seeking approval to engage in commercial manufacture and sell the generic version in America prior to the expiration of the patents-in-suit, the petition said.

Taiho further alleged that Natco's proposed ANDA violates the Lonsuf's patents on six counts.

Natco informed the Japanese drug major that its ANDA will not infringe the patents through "Paragraph IV notice letter."

Under Paragraph IVPatentCertifications, a company can seek FDA approval to market a generic drug before the expiration ofpatentsrelated to the brand-name drug that the generic seeks to copy.

A senior official of a city-based pharmaceutical company saidpatent infringement cases in the US are not uncommon for generic drug makers and the lawsuit will not have any implications on the performance of the copycat makers.



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel